---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-018800"
form_type: "8-K"
ticker: "ACAD"
cik: "0001070494"
company_name: "ACADIA PHARMACEUTICALS INC"
filed_at: "2023-05-08T23:59:59+00:00"
generated_at: "2026-06-15T12:05:23.261732+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Acadia Q1 net loss narrows to $43M; DAYBUE approved and launched for Rett syndrome

## Summary
- NUPLAZID net sales $118.5M, up 3% YoY; demand grew ~2%.
- Net loss $43.0M ($0.27/share) vs $113.1M ($0.70/share) in Q1 2022.
- DAYBUE (trofinetide) FDA-approved March 10; launched April 17 for Rett syndrome.
- Phase 3 pimavanserin trial for negative schizophrenia symptoms nearing enrollment; results expected early 2024.
- 2023 guidance reaffirmed: NUPLAZID sales $520-$550M, R&D $235-$255M, SG&A $360-$380M.

## SEC filing metadata
- accession: 0000950170-23-018800
- form_type: 8-K
- ticker: ACAD
- cik: 0001070494
- company_name: ACADIA PHARMACEUTICALS INC
- filed_at: 2023-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1070494/000095017023018800/0000950170-23-018800-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1070494/000095017023018800/acad-20230508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-018800
- JSON: https://secwatch.observer/filing/0000950170-23-018800.json
- Plain text: https://secwatch.observer/filing/0000950170-23-018800.txt

## Key facts
- Earnings Releases
  ACADIA PHARMACEUTICALS INC reported three months ended March 31, 2023 results: revenue $118.5 million, net income $43.0 million, or $0.27 per common share, EPS $0.27 per common share. Guidance reaffirmed.
  - Period: three months ended March 31, 2023
  - Revenue: $118.5 million
  - Net income: $43.0 million, or $0.27 per common share
  - EPS: $0.27 per common share
  - Guidance: reaffirmed
  - Result: reported results
  source text: language. --- EX-99 (EX-99.1) --- EX-99 Exhibit 99.1 Acadia Pharmaceuticals Reports First Quarter 2023 Financial Results and Operating Overview - 1Q23 NUPLAZID ® net sales of $118.5 million - Announced the U.S. FDA Approval of DAYBUETM (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatric Patients Two Years of Age and Older on March 10, 2023 -
  evidence_url: https://www.sec.gov/Archives/edgar/data/1070494/000095017023018800/0000950170-23-018800-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.